Authors: Boerrigter G.; Burnett Jr J.C.

Source: Expert Opinion on Investigational Drugs, Volume 13, Number 6, 1 June 2004 , pp. 643-652(10)

Publisher: Informa Healthcare

Abstract:

Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are secreted by the heart and play important roles in the compensation of congestive heart failure with their vasodilating, natriuretic, antiproliferative, lusitropic and neurohumoral-modulating properties. Based on these beneficial properties, exogenous BNP was developed as a new treatment for congestive heart failure and approved in the US for acute decompensated heart failure. New therapeutic strategies for heart failure that are currently being investigated include chronic subcutaneous BNP administration and intermittent BNP infusions. Furthermore, strategies combining exogenous BNP with an inhibitor of the BNP-degrading enzyme neutral endopeptidase could contribute to maximising the actions of BNP and reduce the amount of exogenous BNP needed.

Keywords: cyclic guanosine monophosphate; heart failure; natriuretic peptides; nesiritide; neurohumoral activation

Document Type: Review article

DOI: http://dx.doi.org/10.1517/13543784.13.6.643

Publication date: 2004-06-01

More about this publication?

• Editorial Board
• Information for Authors
• Subscribe to this Title
• Terms & Conditions
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Boerrigter G. ;  Burnett Jr J.C.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers